Search Results - "Talbot, D. C."

Self-rated health in individuals with and without disease is associated with multiple biomarkers representing multiple biological domains by Kananen, L., Enroth, L., Raitanen, J., Jylhävä, J., Bürkle, A., Moreno-Villanueva, M., Bernhardt, J., Toussaint, O., Grubeck-Loebenstein, B., Malavolta, M., Basso, A., Piacenza, F., Collino, S., Gonos, E. S., Sikora, E., Gradinaru, D., Jansen, E. H. J. M., Dollé, M. E. T., Salmon, M., Stuetz, W., Weber, D., Grune, T., Breusing, N., Simm, A., Capri, M., Franceschi, C., Slagboom, P. E., Talbot, D. C. S., Libert, C., Koskinen, S., Bruunsgaard, H., Hansen, ÅM., Lund, R., Hurme, M., Jylhä, M.

“…Self-rated health (SRH) is one of the most frequently used indicators in health and social research. Its robust association with mortality in very different…”
Get full text

Reasons given by patients for participating, or not, in Phase 1 cancer trials by Catt, S, Langridge, C, Fallowfield, L, Talbot, D.C, Jenkins, V

“…Abstract Background Communication with patients contemplating Phase 1 cancer trial participation can be challenging. Controversy exists as to whether they are…”
Get full text

Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C by PROPPER, D. J, MCDONALD, A. C, KAYE, S. B, GANESAN, T. S, TALBOT, D. C, HARRIS, A. L, TWELVES, C, MAN, A, THAVASU, P, BALKWILL, F, BRAYBROOKE, J. P, CAPONIGRO, F, GRAF, P, DUTREIX, C, BLACKIE, R

“…N-Benzoyl staurosporine (PKC412) is a protein kinase C inhibitor with antitumor activity in laboratory models. We determined the toxicity of oral PKC412…”
Get full text

Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours by Medley, L, Morel, A N, Farrugia, D, Reed, N, Hayward, N, Davies, J M, Kirichek, O, Thakker, R V, Talbot, D C

“…Background: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic…”
Get full text

Randomised, phase II trial comparing oral capecitabine (Xeloda ) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines by TALBOT, D. C, MOISEYENKO, V, LAWS, S, OSTERWALDER, B, VAN BELLE, S, O'REILLY, S. M, CONEJO, E. Alba, ACKLAND, S, EISENBERG, P, MELNYCHUK, D, PIENKOWSKI, T, BURGER, H-U

“…Capecitabine, an oral fluoropyrimidine carbamate, was designed to generate 5-fluorouracil preferentially at the tumour site. This randomised, phase II trial…”
Get full text

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer by Khan, O A, Blann, A D, Payne, M J, Middleton, M R, Protheroe, A S, Talbot, D C, Taylor, M, Han, C, Patil, M, Harris, A L

“…Background: Combined therapy of metronomic cyclophosphamide, methotrexate and high-dose celecoxib targeting angiogenesis was used in a phase II trial. Methods:…”
Get full text

Isolation of a small molecule inhibitor of DNA base excision repair by Madhusudan, Srinivasan, Smart, Fiona, Shrimpton, Paul, Parsons, Jason L., Gardiner, Laurence, Houlbrook, Sue, Talbot, Denis C., Hammonds, Timothy, Freemont, Paul A., Sternberg, Michael J. E., Dianov, Grigory L., Hickson, Ian D.

“…The base excision repair (BER) pathway is essential for the removal of DNA bases damaged by alkylation or oxidation. A key step in BER is the processing of an…”
Get full text

Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin by SMITH, Ian E, O'BRIEN, Mary E. R, TALBOT, Denis C, NICOLSON, Marianne C, MANSI, Janine L, HICKISH, Tamas F, NORTON, Alison, ASHLEY, Susan

“…So far there are no published data on optimal duration of chemotherapy for advanced non-small-cell lung cancer (NSCLC); six or more courses are usually…”
Get full text

Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer by Talbot, B.C., Brown, P.D.

Get full text

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents by HAN, C, BRAYBROOKE, J. P, DEPLANQUE, G, TAYLOR, M, MACKINTOSH, D, KAUR, K, SAMOURI, K, GANESAN, T. S, HARRIS, A. L, TALBOT, D. C

“…The aims of this study were to identify prognostic variables for toxicity and survival in patients with cancer participating in phase I clinical trials and…”
Get full text

A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours by WALL, L, TALBOT, D. C, BRADBURY, P, JODRELL, Dl

“…BB-3644 is an oral, broad-spectrum matrix metalloproteinase inhibitor (MMPI) structurally related to marimastat and BB-94. It is also >10-fold more active than…”
Get full text

Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer by KOUKOURAKIS, M. I, GIATROMANOLAKI, A, O'BYRNE, K. J, COMLEY, M, WHITEHOUSE, R. M, TALBOT, D. C, GATTER, K. C, HARRIS, A. L

“…Angiogenesis is a recently described prognostic factor in non-small-cell lung cancer. Platelet-derived endothelial cell growth factor (PD-ECGF), shown to be…”
Get full text

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069 by PATTERSON, A. V, SAUNDERS, M. P, CHINJE, E. C, TALBOT, D. C, HARRIS, A. L, STRATFORD, I. J

“…P450 reductase (NADPH: cytochrome c (P450) reductase, EC 1.6.2.4) plays an important role in the reductive activation of the bioreductive drug tirapazamine…”
Get full text

Increased sensitivity to the prodrug 5'-deoxy-5-fluorouridine and modulation of 5-fluoro-2'-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase by PATTERSON, A. V, ZHANG, H, MOGHADDAM, A, BICKNELL, R, TALBOT, D. C, STRATFORD, I. J, HARRIS, A. L

“…Platelet-derived endothelial cell growth factor (PD-ECGF) is identical to human thymidine phosphorylase (dThdPase). The human MCF-7 breast cancer cell line was…”
Get full text

Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer by JONES, P. H, CHRISTODOULOS, K, TALBOT, D. C, GANESAN, T. S, HARRIS, A. L, DOBBS, N, THAVASU, P, BALKWILL, F, BLANN, A. D, CAINE, G. J, KUMAR, S, KAKKAR, A. J, GOMPERTZ, N

“…Marimastat, low molecular weight heparins and captopril have antiangiogenic activity in vitro and in animal models. We studied the safety and efficacy of the…”
Get full text

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer by Basu, B., Krebs, M.G., Sundar, R., Wilson, R.H., Spicer, J., Jones, R., Brada, M., Talbot, D.C., Steele, N., Ingles Garces, A.H., Brugger, W., Harrington, E.A., Evans, J., Hall, E., Tovey, H., de Oliveira, F.M., Carreira, S., Swales, K., Ruddle, R., Raynaud, F.I., Purchase, B., Dawes, J.C., Parmar, M., Turner, A.J., Tunariu, N., Banerjee, S., de Bono, J.S., Banerji, U.

“…We have previously shown that raised p-S6K levels correlate with resistance to chemotherapy in ovarian cancer. We hypothesised that inhibiting p-S6K signalling…”
Get full text

A phase II study of bryostatin 1 in metastatic malignant melanoma by PROPPER, D. J, MACAULAY, V, O'BYRNE, K. J, BRAYBROOKE, J. P, WILNER, S. M, GANESAN, T. S, TALBOT, D. C, HARRIS, A. L

“…Bryostatin 1 is a protein kinase C partial agonist which has both antineoplastic and immune-stimulatory properties, including the induction of cytokine release…”
Get full text

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma by DEPLANQUE, G, MADHUSUDAN, S, JONES, P. H, WELLMANN, S, CHRISTODOULOS, K, TALBOT, D. C, GANESAN, T. S, BLANN, A, HARRIS, A. L

“…IM862 is a naturally occurring dipeptide (L-glu-L-trp) with immunomodulatory and antiangiogenic properties. A significant anticancer activity has been reported…”
Get full text

Phase I Study of Intrapleural Batimastat (BB-94), a Matrix Metalloproteinase Inhibitor, in the Treatment of Malignant Pleural Effusions by MACAULAY, V. M, O'BYRNE, K. J, SAUNDERS, M. P, BRAYBROOKE, J. P, LONG, L, GLEESON, F, MASON, C. S, HARRIS, A. L, BROWN, P, TALBOT, D. C

“…Tumor cells and associated stromal cells secrete matrix metalloproteinases (MMPs), contributing to invasion, angiogenesis, and metastasis. Batimastat (BB-94)…”
Get full text

The development of a structured rating schedule (the BAS) to assess skills in breaking bad news by MILLER, S. J, HOPE, T, TALBOT, D. C

“…There has been considerable interest in how doctors break bad news, with calls from within the profession and from patients for doctors to improve their…”
Get full text